Advertisement

Tumor Biology

, Volume 37, Issue 8, pp 11073–11079 | Cite as

CIZ1 interacts with YAP and activates its transcriptional activity in hepatocellular carcinoma cells

  • Liu Lei
  • Jinsheng Wu
  • Dianhua Gu
  • Hui Liu
  • Shaochuang Wang
Original Article

Abstract

Dysregulation of Hippo-Yes-associate protein (YAP) signaling has important roles in the tumorigenesis of hepatocellular carcinoma (HCC). Our previous studies have shown that Cip1 interacting zinc finger protein 1 (CIZ1) activated YAP signaling in the HCC cells and promoted the growth and migration of cancer cells. However, the mechanisms for the activation of YAP signaling by CIZ1 are unknown. In this study, it was found that CIZ1 interacted with the transcriptional factor YAP in HCC cells. The nuclear matrix anchor domain of CIZ1 is responsible for its interaction with YAP. Moreover, CIZ1 enhanced the interaction between YAP and TEAD. Knocking down the expression of CIZ1 impaired the transcriptional activity as well as the biological functions of YAP. Taken together, our study demonstrated that CIZ1 is a positive regulator of YAP signaling, and CIZ1 might be a therapeutic target for HCC.

Keywords

CIZ1 YAP HCC Cell growth and migration 

Notes

Acknowledgments

This work was supported by International Science and Technology Cooperation Program of the Ministry of Science and Technology (2011DFA32980), One Hundred Person Project of the Shanghai Health (XBR2013117), and the National Natural Science Foundation of China (NSFC81271694).

Compliance with ethical standards

Conflicts of interest

None

References

  1. 1.
    Yu FX, Zhao B, Guan KL. Hippo pathway in organ size control, tissue homeostasis, and cancer. Cell. 2015;163(4):811–28.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Badouel C, McNeill H. SnapShot: the Hippo signaling pathway. Cell. 2011;145(3):484–484 e1.CrossRefPubMedGoogle Scholar
  3. 3.
    Zhao B, Guan KL. Hippo pathway key to ploidy checkpoint. Cell. 2014;158(4):695–6.CrossRefPubMedGoogle Scholar
  4. 4.
    Zhang W et al. VGLL4 functions as a new tumor suppressor in lung cancer by negatively regulating the YAP-TEAD transcriptional complex. Cell Res. 2014;24(3):331–43.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Zhang K et al. YAP and TAZ take center stage in cancer. Biochemistry. 2015;54(43):6555–66.CrossRefPubMedGoogle Scholar
  6. 6.
    Avril T, Chevet E. Proteostasis trumps YAP in colon cancer. Sci Signal. 2015;8(397):fs18.CrossRefPubMedGoogle Scholar
  7. 7.
    Yang S et al. Active YAP promotes pancreatic cancer cell motility, invasion and tumorigenesis in a mitotic phosphorylation-dependent manner through LPAR3. Oncotarget. 2015;6(34):36019–31.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Zhao B, Lei Q, Guan KL. Mst out and HCC in. Cancer Cell. 2009;16(5):363–4.CrossRefPubMedGoogle Scholar
  9. 9.
    Jie L et al. The Hippo-yes association protein pathway in liver cancer. Gastroenterol Res Pract. 2013;2013:187070.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Wang C et al. Knockdown of yes-associated protein inhibits proliferation and downregulates large tumor suppressor 1 expression in MHCC97H human hepatocellular carcinoma cells. Mol Med Rep. 2015;11(6):4101–8.PubMedPubMedCentralGoogle Scholar
  11. 11.
    Perra A et al. YAP activation is an early event and a potential therapeutic target in liver cancer development. J Hepatol. 2014;61(5):1088–96.CrossRefPubMedGoogle Scholar
  12. 12.
    Han SX et al. Expression and clinical significance of YAP, TAZ, and AREG in hepatocellular carcinoma. J Immunol Res. 2014;2014:261365.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Li H et al. Yes-associated protein expression is a predictive marker for recurrence of hepatocellular carcinoma after liver transplantation. Dig Surg. 2014;31(6):468–78.CrossRefPubMedGoogle Scholar
  14. 14.
    Liu AM, Poon RT, Luk JM. MicroRNA-375 targets Hippo-signaling effector YAP in liver cancer and inhibits tumor properties. Biochem Biophys Res Commun. 2010;394(3):623–7.CrossRefPubMedGoogle Scholar
  15. 15.
    Wang Y et al. MiR-506 suppresses proliferation of hepatoma cells through targeting YAP mRNA 3'UTR. Acta Pharmacol Sin. 2014;35(9):1207–14.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Higashi T et al. miR-9-3p plays a tumour-suppressor role by targeting TAZ (WWTR1) in hepatocellular carcinoma cells. Br J Cancer. 2015;113(2):252–8.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Li X et al. Co-activation of PIK3CA and Yap promotes development of hepatocellular and cholangiocellular tumors in mouse and human liver. Oncotarget. 2015;6(12):10102–15.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Li L et al. MEK1 promotes YAP and their interaction is critical for tumorigenesis in liver cancer. FEBS Lett. 2013;587(24):3921–7.CrossRefPubMedGoogle Scholar
  19. 19.
    Xu MZ et al. AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma. Oncogene. 2011;30(10):1229–40.CrossRefPubMedGoogle Scholar
  20. 20.
    Copeland NA et al. Cyclin-A-CDK2-mediated phosphorylation of CIZ1 blocks replisome formation and initiation of mammalian DNA replication. J Cell Sci. 2015;128(8):1518–27.CrossRefPubMedGoogle Scholar
  21. 21.
    Zhang D et al. CIZ1 promoted the growth and migration of gallbladder cancer cells. Tumour Biol. 2015;36(4):2583–91.CrossRefPubMedGoogle Scholar
  22. 22.
    Warder DE, Keherly MJ. Ciz1, Cip1 interacting zinc finger protein 1 binds the consensus DNA sequence ARYSR(0–2)YYAC. J Biomed Sci. 2003;10(4):406–17.PubMedGoogle Scholar
  23. 23.
    Higgins G et al. Variant Ciz1 is a circulating biomarker for early-stage lung cancer. Proc Natl Acad Sci U S A. 2012;109(45):E3128–35.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Takigawa Y, Brown AM. Wnt signaling in liver cancer. Curr Drug Targets. 2008;9(11):1013–24.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  1. 1.Department of Hepatobiliary & Pancreatic Surgery, Huai’an First People’s HospitalNanjing Medical UniversityHuai’anChina
  2. 2.Eastern Hepatobiliary Surgery HospitalSecond Military Medical UniversityShanghaiChina

Personalised recommendations